Form 4: Champions Oncology Director Acquires Stock Options

Champions Oncology Director and 10% owner Scott R. Tobin acquired 25,460 stock options with an exercise price of $6.80, vesting over 12 months.

Summary

• Scott R. Tobin, a Director and 10% Owner of Champions Oncology, Inc. (CSBR), acquired 25,460 derivative securities in the form of options to purchase Common Stock.
• The transaction date for this acquisition was November 5, 2025.
• The exercise price for these options is $6.80 per share.
• The options vest over a twelve-month period, with specific vesting dates on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026.
• These options are exercisable over a ten-year period, with an expiration date of November 5, 2035.
• Following this transaction, Scott R. Tobin beneficially owns 25,460 derivative securities.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a Director and 10% owner is generally viewed as a positive signal, indicating insider confidence in the company's future prospects and alignment of interests with shareholders.

Positives

• The acquisition of stock options by a Director and 10% owner, Scott R. Tobin, signals confidence in the company's future performance.
• The options have a ten-year exercise period, providing long-term incentive for the insider.

Future Outlook

The filing indicates a long-term incentive structure for a key insider, with options vesting over the next year and exercisable for ten years, suggesting an expectation of future value creation.

Industry Context

Insider purchases, particularly by significant shareholders and directors, are often viewed by the market as a positive signal, indicating that those with the most intimate knowledge of the company believe its stock is undervalued or has strong future prospects. This transaction aligns with typical equity compensation and incentive structures for corporate leadership in the biotechnology or oncology services sector.

Related Party Transactions

• The acquisition of stock options by a Director and 10% owner is an insider transaction, which is a form of related party dealing, but it is a standard compensation mechanism rather than an unusual transaction.

Stakeholder Impact

• Shareholders may view this as a positive signal of insider confidence, potentially leading to increased investor interest.
• Management/Employees: Reinforces alignment of interests between leadership and company performance.

Next Steps

• The options will vest in four installments on November 5, 2025, February 5, 2026, May 5, 2026, and August 5, 2026.
• The options will be exercisable until their expiration date of November 5, 2035.

Key Dates

Keywords

Champions Oncology, CSBR, Stock Options, Insider Transaction, Form 4, Director, 10% Owner, Equity Compensation, Scott R. Tobin